Specify dispense as written (DAW) on every COPAXONE® prescription, new and refill, to help ensure consistency for your RMS patients.

why daw is important

COPAXONE’S COMMITMENT TO RELAPSING FORMS OF MULTIPLE SCLEROSIS (RMS) IS

PART OF THE PACKAGE

COPAXONE® (glatiramer acetate injection) 40 mg package.

Making the patient experience our priority

Teva Shared Solutions® Stacked Logo.

Shared Solutions® Digital Services delivers accessible, easy-to-use and understand digital touchpoints and resources to your patients

Past, present, future.

TEVA SPONSORED 27-YEAR OPEN-LABEL EXTENSION STUDY

Found safety profile to be consistent with pivotal trials and suggested earlier initiation of glatiramer acetate could lead to sustained results in RMS treatment. Help raise patient awareness about the longevity of COPAXONE®.3

VIEW EFFICACY DATA

TEVA SHARED SOLUTIONS® DIGITAL SERVICES

Help your patients navigate COPAXONE® treatment from wherever they are 24/7. Direct them to this wide range of easy-to-use and easy-to-access digital services.

VIEW RESOURCES

References:

1.

COPAXONE® (glatiramer acetate injection) Current Prescribing Information Parsippany, NJ. Teva Neuroscience, Inc.

2.

Schellekens H, Klinger E, Mühlebach S, Brin J-F, Storm G, Crommelin DJA. The therapeutic equivalence of complex drugs. Regul Toxicol Pharmacol. 2011;59(1):176-183. doi:10.1016/j.yrtph.2010.09.021

3.

Ford CC, Cohen JA, Goodman AD, et al. Early versus delayed treatment with glatiramer acetate: Analysis of up to 27 years of continuous follow-up in a US open-label extension study. Mult Scler. 2022;28(11):1729-1743. doi:10.1177/13524585221094239

You are about to leave COPAXONEHCP.com and enter a website operated by a third party.

Would you like to continue?

Allyable tool icon